"It is time to close the book on the amyloid hypothesis", it is one of the conclusions. Good thread.
---
RT @schrag_matthew
My thoughts on the phase 3 results of Alzheimer's drug lecanemab from Biogen and Eisai, presented at #CTAD #CTAD22 and published this evening in the @NEJM. Major takeaway – this is NOT the breakthrough we have been waiting for. Key points:
https://twitter.com/schrag_matthew/status/1597860167806111744
@domhenri Very good thread, as a minor point, this is why papers should have the data files attached: "The much trumpeted "27% slowing" is a relative value - the absolute difference on this test was 2.5%. In this image, I have re-scaled the result from the NEJM paper to include the absolute difference. [Values approximated using a graph extractor.]"
